Telix Pharmaceuticals Ltd
F:T3X
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Telix Pharmaceuticals Ltd
F:T3X
|
AU |
|
Plug Power Inc
NASDAQ:PLUG
|
US |
Intrinsic Value
The intrinsic value of 
Telix Pharmaceuticals Ltd (T3X) under the Base Case is 11.359 EUR per share.
Compared with the current market price of 8.766 EUR, the stock appears
Undervalued by 23% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Telix Pharmaceuticals Does
Telix Pharmaceuticals is a biopharmaceutical company that develops and sells radiopharmaceuticals, which are medicines that use radioactive tracers to help doctors find or treat disease. Its best-known products are imaging agents used in cancer care, especially for prostate cancer, and it also develops therapies that target tumors more directly.
- Headquarters
- Australia AU
- Employees
- 1 120
- IPO date
- Nov 15, 2017
Telix Pharmaceuticals has a wide economic moat
Telix Pharmaceuticals Ltd possesses a wide economic moat, providing strong and durable advantages that protect its market position and profitability.
Read the full moat analysis
Earnings Waterfall
Telix Pharmaceuticals Ltd
The intrinsic value for Telix Pharmaceuticals Ltd (T3X) under the Base Case is 11.359 EUR.
Compared with the current market price of 8.766 EUR, the stock appears Undervalued by 23% .
